Testpage/Main 1

June 17, 2009: Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet The ATLAS ACS-TIMI 46 Study Group investigators reported today in The Lancet that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51).

<googlenewsdynamic sites="news.google.com" numresults="30" newstitle="Today in Medicine">newstitle=</googlenewsdynamic>